Hemagen Diagnostics, Inc.
HMGN · OTC
9/30/2012 | 6/30/2012 | 3/31/2012 | 12/31/2011 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.14 | 0.02 | 0.00 | -0.02 |
| FCF Yield | -11.70% | 0.24% | -26.66% | -83.89% |
| EV / EBITDA | -900.33 | 198.33 | -62.88 | -24.04 |
| Quality | ||||
| ROIC | -2.97% | -0.77% | -7.48% | -14.74% |
| Gross Margin | 45.91% | 47.84% | 31.54% | 36.79% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -8.17% | -6.27% | -3.51% | -2.05% |
| Free Cash Flow Growth | -3,780.78% | 101.19% | 54.59% | -668.77% |
| Safety | ||||
| Net Debt / EBITDA | -823.17 | 176.13 | -57.39 | -22.50 |
| Interest Coverage | -0.36 | -0.10 | -1.11 | -2.24 |
| Efficiency | ||||
| Inventory Turnover | 0.35 | 0.36 | 0.56 | 0.45 |
| Cash Conversion Cycle | 249.24 | 304.42 | 209.39 | 235.78 |